Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Debt (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 8 years of Non-Current Debt data on record, last reported at $20.9 million in Q3 2025.

  • For Q3 2025, Non-Current Debt rose 1.79% year-over-year to $20.9 million; the TTM value through Sep 2025 reached $20.9 million, up 1.79%, while the annual FY2024 figure was $20.6 million, 1.87% up from the prior year.
  • Non-Current Debt reached $20.9 million in Q3 2025 per VRDN's latest filing, up from $12.4 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $20.9 million in Q3 2025 and bottomed at $12.4 million in Q2 2025.
  • Average Non-Current Debt over 3 years is $19.0 million, with a median of $20.5 million recorded in 2024.
  • Peak YoY movement for Non-Current Debt: increased 1.87% in 2024, then fell 29.36% in 2025.
  • A 3-year view of Non-Current Debt shows it stood at $20.2 million in 2023, then rose by 1.87% to $20.6 million in 2024, then increased by 1.5% to $20.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $20.9 million in Q3 2025, $12.4 million in Q2 2025, and $20.7 million in Q1 2025.